Using Aspirin to Improve Immunological Features of Ovarian Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Aspirin 325mg

"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."

DRUG

Placebo

"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."

Trial Locations (4)

22031

RECRUITING

Inova Schar Cancer Institute, Fairfax

22903

RECRUITING

University of Virginia Comprehensive Cancer Center, Charlottesville

33612

RECRUITING

Moffitt Cancer Center, Tampa

97239

RECRUITING

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Sharp

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER